干燥综合征（Sjögren's syndrome，SS）是一种以淋巴细胞浸润为特征的慢性自身免疫性疾病，由于外分泌腺分泌减少，临床上主要表现为口、眼干等症状，常可累及多个脏器，目前尚缺乏可靠的血清学诊断方法。临床应用最多的检测抗体为抗Ro/SSA抗体和抗La/SSB抗体，鉴于这些抗体在诊断SS中的阳性检出率不高，有必要探索新的自身抗体，以提高诊断率。目前新发现的一些抗体有助于SS早期诊断及对SS相关多系统损害有预测作用。本文作者针对目前国内外最新的SS相关自身抗体的研究进展进行综述。

[1] MARIETTE X,CRISWELL L A.Primary Sjogren's syndrome[J].N Engl J Med,2018,378(10):931-939.
[2] WANG B,CHEN S,ZHENG Q,et al.Early diagnosis and treatment for Sjogren's syndrome:current challenges,redefined disease stages and future prospects[J/OL].J Autoimmun,2020,117:102590.doi:10.1016/j.jaut.2020.102590
[3] 何菁,方万,栗占国.四种自身抗体在原发性干燥综合征诊断中的合理应用[J].中华内科杂志,2008,47(5):366-368.
[4] HENRIKSSON G.Presymptomatic autoantibodies in Sjogren's syndrome:what significance do they hold for the clinic?[J].Expert Rev Clin Immunol,2014,10(7):815-817.
[5] SHEN L,SURESH L,LINDEMANN M,et al.Novel autoantibodies in Sjogren's syndrome[J].Clin Immunol,2012,145(3):251-255.
[6] XUAN J,WANG Y,XIONG Y,et al.Investigation of autoantibodies to SP-1 in Chinese patients with primary Sjogren's syndrome[J].Clin Immunol,2018,188:58-63.
[7] EVERETT S,VISHWANATH S,CAVERO V,et al.Analysis of novel Sjogren's syndrome autoantibodies in patients with dry eyes[J].BMC Ophthalmol,2017,17(1):20.
[8] SURESH L,MALYAVANTHAM K,SHEN L,et al.Investigation of novel autoantibodies in Sjogren's syndrome utilizing Sera from the Sjogren's international collaborative clinical alliance cohort[J].BMC Ophthalmol,2015,15:38.
[9] TER BORG E,KELDER J.Polyarthritis in primary Sjögren's syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up[J].Clin Rheumatol,2016,35(3):649-655.
[10] NEZOS A,CINOKU I,MAVRAGANI C P,et al.Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome[J].Clin Immunol,2017,183:300-303.
[11] FIORENTINO D F,PRESBY M,BAER A N,et al.PUF60:a prominent new target of the autoimmune response in dermatomyositis and Sjogren's syndrome[J].Ann Rheum Dis,2016,75(6):1145-1151.
[12] RIETVELD A,VAN DEN HOOGEN L L,BIZZARO N,et al.Autoantibodies to cytosolic 5'-nucleotidase 1A in primary Sjogren's syndrome and systemic lupus erythematosus[J].Front Immunol,2018,9:1200.
[13] ABBARA S,SEROR R,HENRY J,et al.Anti-RNP positivity in primary Sjogren's syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement[J].RMD Open,2019,5(2):e001033.
[14] TAKEMOTO F,KATORI H,SAWA N,et al.Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome[J].Nephron Physiol,2007,106(4):p63-68.
[15] PERTOVAARA M,BOOTORABI F,KUUSLAHTI M,et al.Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjogren's syndrome[J].Rheumatology (Oxford),2011,50(8):1453-1457.
[16] SOYFOO M,NICAISE C.Pathophysiologic role of Interleukin-33/ST2 in Sjögren's syndrome[J/OL].Autoimmunity reviews,2021,20(3):102756.doi:10.1016/j.autrev.2021.102756.
[17] ZHAO L,YAO L,YUAN L,et al.Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's syndrome[J].Cytokine,2013,64(1):22-24.
[18] SHIEH J M,TSENG H Y,JUNG F,et al.Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model[J/OL].Mediators Inflamm,2019,2019:7947596.doi:10.1155/2019/7947596.
[19] YANG L,BAI L,WEI F,et al.Autoantibodies against interferon-gamma reduce the frequency of pulmonary fibrosis and concentration of C-reactive protein in patients with primary Sjogren's syndrome[J].Mod Rheumatol,2015,25(2):325-327.
[20] PARK K,HABERBERGER R V,GORDON T P,et al.Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjogren's syndrome[J].Arthritis Rheum,2011,63(5):1426-1434.
[21] GEBRESELASSIE A,ADULI F,HOWELL C D.Rheumatologic diseases and the liver[J].Clin Liver Dis,2019,23(2):247-261.
[22] PODGÓRSKA J,WEREL P,KLAPACZYSKI J,et al.Liver involvement in rheumatic diseases[J].Reumatologia,2020,58(5):289-296.
[23] CSEPREGI A,SZODORAY P,ZEHER M.Do autoantibodies predict autoimmune liver disease in primary Sjögren's syndrome? Data of 180 patients upon a 5 year follow-up[J].Scand J Immunol,2002,56(6):623-629.
[24] LIEDTKE W,LEMAN E E,FYFFE R E W,et al.Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems[J].Am J Pathol,2002,160(2):469-480.
[25] DUDA S,WITTE T,STANGEL M,et al.Autoantibodies binding to stathmin-4:new marker for polyneuropathy in primary Sjogren's syndrome[J].Immunol Res,2017,65(6):1099-1102.
[26] PITTOCK S,LENNON V,DE SEZE J,et al.Neuromyelitis optica and non organ-specific autoimmunity[J].Arch Neurol,2008,65(1):78-83.
[27] BIRNBAUM J,ATRI N M,BAER A N,et al.Relationship between neuromyelitis optica spectrum disorder and Sjogren's syndrome:central nervous system extraglandular disease or unrelated,co-occurring autoimmunity?[J].Arthritis Care Res (Hoboken),2017,69(7):1069-1075.
[28] BIRNBAUM J,HOKE A,LALJI A,et al.Brief report:anti-calponin 3 autoantibodies:a newly identified specificity in patients with Sjogren's syndrome[J].Arthritis Rheumatol,2018,70(10):1610-1616.
[29] STERGIOU I E,POULAKI A,VOULGARELIS M.Pathogenetic mechanisms implicated in Sjogren's syndrome lymphomagenesis:a review of the literature[J].J Clin Med,2020,9(12):3794.
[30] CUI L,ELZKRA N,XU S,et al.Investigation of three potential autoantibodies in Sjogren's syndrome and associated MALT lymphoma[J].Oncotarget,2017,8(18):30039-30049.
[31] KAPSOGEORGOU E K,PAPAGEORGIOU A,PROTOGEROU A D,et al.Low miR200b-5p levels in minor salivary glands:a novel molecular marker predicting lymphoma development in patients with Sjogren's syndrome[J].Ann Rheum Dis,2018,77(8):1200-1207.
[32] HU Y H,ZHOU P F,LONG G F,et al.Elevated plasma P-selectin autoantibodies in primary Sjogren syndrome patients with thrombocytopenia[J].Med Sci Monit,2015,21:3690-3695.